EMA Starts Safety Review of CAR T-Cell Medicines

News
Article

The agency is reviewing data on secondary malignancies related to T-cells for approved CAR T-cell medicines.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

The European Medicines Agency (EMA) announced on Jan. 12, 2024 that its Pharmacovigilance Risk Assessment Committee (PRAC) was beginning a review of data on secondary malignancies related to T-cells for six approved chimeric antigen receptor (CAR) T-cell medicines. The committee is reviewing data from 23 cases of T-cell lymphoma or leukemia in the European Union’s EudraVigilance adverse event database.

According to EMA, secondary malignancies are those that develop when a cancer patient develops a second cancer that is different from the original cancer. This risk was considered at the time of authorization of the impacted drugs and included in risk management plans. The drugs have been monitored, and the marketing authorization holders are required to submit interim results from long-term and efficacy studies.

The impacted drugs—Breyanzi, Carvykti, Kymriah, Tecartus, and Yescarta—are approved in the EU and are used to treat blood cancers such as B-cell leukemia, B-cell lymphoma, follicular lymphoma, multiple myeloma, and mantle cell lymphoma in patients whose cancer has relapsed or has stopped responding to previous treatment. They are “personalized cancer immunotherapies where patients' white blood cells (T-cells) are reprogrammed and reinjected to attack the cancer.”

Source: EMA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes